ERBB3 and melanoma: While melanoma cell populations that express high levels of RTK may be selected and expand following MAPK inhibitor treatment, FOXD3 is increased by BRAF inhibitor treatment and transcriptionally induces ERBB3 expression, providing an early adaptive resistance response in melanoma [117,118,119].